Outlook Therapeutics Announces Completion of Warrant Restructuring
Outlook Therapeutics, Inc. (OTLK)
Last outlook therapeutics, inc. earnings: 2/14 08:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
CRANBURY, N.J., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a?late clinical-stage?biopharmaceutical company?working to develop the first FDA-approved ophthalmic formulation of bevacizumab?for use in retinal?indications, today announced that it has completed the previously announced warrant restructuring. Effective December 23, 2019, with consent of the required holders of the Outlook Therapeutics warrants issued in the Company’s April 2019 underwritten public offering (the “April Warrants”), the Company amended the April Warrants to reduce the exercise price to $0.232 per share and allow for the immediate cashless exercise of the April Warrants. In addition, the expiration date for all of the April Warrants was changed to 5:00 pm EST on December 24, 2019. As a result of these amended terms, all outstanding April Warrants (approximately 10.4 million) have now been exercised in full resulting in the issuance of approximately 8.2 mill
Show less
Read more
Impact Snapshot
Event Time:
OTLK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OTLK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OTLK alerts
High impacting Outlook Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
OTLK
News
- Outlook Therapeutics, Inc. (NASDAQ: OTLK) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $50.00 price target on the stock.MarketBeat
- Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its price target raised by analysts at HC Wainwright from $1.50 to $30.00. They now have a "buy" rating on the stock.MarketBeat
- Outlook Therapeutics stock jumps on positive EU CHMP opinion for its wet AMD treatment [Seeking Alpha]Seeking Alpha
- Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD [Yahoo! Finance]Yahoo! Finance
- Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMDGlobeNewswire
OTLK
Earnings
- 2/14/24 - Beat
OTLK
Sec Filings
- 3/28/24 - Form S-8
- 3/28/24 - Form S-3
- 3/28/24 - Form SC
- OTLK's page on the SEC website